Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab in patients with prurigo nodularis (PN) has been accepted as an oral presentation at the 12th World Congress on Itch (WCI), being held in Miami on Nov 5-7, 2023.
Presentation details are below:
Abstract Title: Barzolvolimab demonstrates safety and clinically meaningful activity in moderate-severe prurigo nodularis
Presenting Author: Martin Metz, M.D., Professor of Dermatology and Allergy at Charité – Universitätsmedizin in Berlin
Session: Hot Topics
Date/Time: Tuesday, November 7 at 3:20 PM – 3:28 PM ET
The Phase 1b multi-center, randomized, double-blind, placebo-controlled trial is designed to study barzolvolimab in patients with prurigo nodularis (PN), a chronic skin disease characterized by the development of hard, intensely itchy (pruritic) nodules on the skin.